Reuters

Taro Announces Merger Agreement with Sun Pharma

Retrieved on: 
Wednesday, January 17, 2024

MUMBAI, India and NEW YORK, Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.

Key Points: 
  • Uday Baldota, Chief Executive Officer of Taro, said, "Taro is committed to delivering high quality products to our patients and customers around the world.
  • The merger agreement was unanimously recommended by the Special Committee, which was formed by Taro's Board of Directors to consider Sun Pharma's proposal.
  • Taro will furnish to the U.S. Securities and Exchange Commission (the "SEC") a current report on Form 6‑K regarding the merger, which will include as an exhibit thereto the merger agreement.
  • In connection with the proposed transaction, Taro will prepare and mail to its shareholders a proxy statement that will include a copy of the merger agreement.

Taro Announces Merger Agreement with Sun Pharma

Retrieved on: 
Wednesday, January 17, 2024

MUMBAI, India and NEW YORK, Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.

Key Points: 
  • Uday Baldota, Chief Executive Officer of Taro, said, "Taro is committed to delivering high quality products to our patients and customers around the world.
  • The merger agreement was unanimously recommended by the Special Committee, which was formed by Taro's Board of Directors to consider Sun Pharma's proposal.
  • Taro will furnish to the U.S. Securities and Exchange Commission (the "SEC") a current report on Form 6‑K regarding the merger, which will include as an exhibit thereto the merger agreement.
  • In connection with the proposed transaction, Taro will prepare and mail to its shareholders a proxy statement that will include a copy of the merger agreement.

Thomson Reuters to Host Investor Webcast on Pagero Acquisition

Retrieved on: 
Tuesday, January 16, 2024

TORONTO, Jan. 16, 2024 /PRNewswire/ -- Thomson Reuters (NYSE, TSX: TRI) announced today that it will hold an investor webcast to discuss its acquisition of Pagero, on Friday, January 19, 2024, at 8.30 a.m. EST.

Key Points: 
  • TORONTO, Jan. 16, 2024 /PRNewswire/ -- Thomson Reuters (NYSE, TSX: TRI) announced today that it will hold an investor webcast to discuss its acquisition of Pagero, on Friday, January 19, 2024, at 8.30 a.m. EST.
  • The webcast will feature presentations by Steve Hasker, president and chief executive officer, and Mike Eastwood, chief financial officer.
  • Pagero is a global leader in e-invoicing and indirect tax solutions, which it delivers through its Smart Business Network.
  • You can access the webcast by visiting the " Investor Relations " section of the Thomson Reuters website.

MICROVAST HOLDINGS, INC. (NASDAQ: MVST) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Microvast Holdings, Inc.

Retrieved on: 
Tuesday, January 16, 2024

If you purchased or acquired Microvast securities, and/or would like to discuss your legal rights and options please visit Microvast Holdings, Inc.

Key Points: 
  • If you purchased or acquired Microvast securities, and/or would like to discuss your legal rights and options please visit Microvast Holdings, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than February 5, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Veradigm, Fisker, Microvast, and Eagle Pharmaceuticals and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, January 16, 2024

Then, on June 13, 2023, Veradigm revealed that it had identified additional revenue misstatements dating back to fiscal year 2020.

Key Points: 
  • Then, on June 13, 2023, Veradigm revealed that it had identified additional revenue misstatements dating back to fiscal year 2020.
  • The Company had previously announced former CAO, John Finnucan (“Finnucan”) provided notice of intent to resign on September 19, 2023, effective October 27, 2023.
  • Then, on November 29, 2023, before the market opened, Eagle Pharmaceuticals disclosed that Scott Tarriff, the Company’s President and Chief Executive Officer resigned.
  • For more information on the Eagle Pharmaceuticals class action go to: https://bespc.com/cases/EGRX

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Driven, and Maison Solutions and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 12, 2024

On May 22, 2023, after the market closed, Reuters reported the DOE would not award Microvast the Grant.

Key Points: 
  • On May 22, 2023, after the market closed, Reuters reported the DOE would not award Microvast the Grant.
  • In a call with congressional staff that evening, the DOE confirmed negotiations with Microvast concerning the Grant had been cancelled.
  • For more information on the Microvast class action go to: https://bespc.com/cases/MVST
    Driven is the largest automotive services company in North America.
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

B. Riley (RILY) Shares Fall After Short Seller Questions Company’s Ties to FRG Executive Linked to Criminal Investigation - Hagens Berman

Retrieved on: 
Thursday, January 11, 2024

SAN FRANCISCO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges B. Riley Financial, Inc. (NASDAQ: RILY) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges B. Riley Financial, Inc. (NASDAQ: RILY) investors who suffered substantial losses to submit your losses now .
  • “We are investigating the accuracy of B. Riley’s statements concerning Franchise Group (“FRG”) and knowledge of Brian Kahn’s alleged activities,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
  • On Aug. 28, 2023, B. Riley announced it invested $216.5 million in an equity financing to facilitate the $2.8 billion management-led acquisition of FRG, a formerly public company controlled by Brian Kahn.
  • In the aftermath, B. Riley has marked down the value of its investment in FRG.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Microvast Holdings, Inc. - MVST

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Microvast Holdings, Inc. (“Microvast” or the “Company”) (NASDAQ: MVST).

Key Points: 
  • NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Microvast Holdings, Inc. (“Microvast” or the “Company”) (NASDAQ: MVST).
  • The investigation concerns whether Microvast and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Then, on May 22, 2023, after the market closed, Reuters reported that the DOE would not award Microvast the Grant.
  • In a call with congressional staff that evening, the DOE confirmed negotiations with Microvast concerning the Grant had been cancelled.

MICROVAST SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Microvast To Contact Him Directly To Discuss Their Options

Retrieved on: 
Wednesday, January 10, 2024

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Microvast Holdings, Inc. (“Microvast” or the “Company”) (NASDAQ: MVST) and reminds investors of the February 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • On May 22, 2023, after the market closed, Reuters reported the DOE would not award Microvast the Grant.
  • In a call with congressional staff that evening, the DOE confirmed negotiations with Microvast concerning the Grant had been cancelled.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Microvast’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Investment Opportunities Abound in 2024, Say Natixis Affiliated Investment Managers

Retrieved on: 
Wednesday, January 10, 2024

At least one Natixis Affiliated Investment Manager and one of our strategists believes the long-running Dollar bull market is in trouble.

Key Points: 
  • At least one Natixis Affiliated Investment Manager and one of our strategists believes the long-running Dollar bull market is in trouble.
  • Thus, the ability of an active investment to achieve its objectives will depend on the effectiveness of the investment manager.
  • The investment management subsidiaries of Natixis Investment Managers mentioned in this presentation conduct any investment management activities only in and from the jurisdictions in which they are licensed or authorized.
  • Natixis Distribution, LLC and Natixis Advisors, LLC are located at 888 Boylston Street, Suite 800, Boston, MA 02199.